TORONTO & WINNIPEG, Canada, April 10 /CNW/ - Cangene Corporation today announces that Canadian Blood Services and Héma-Québec have signed five-year agreements to purchase three of Cangene’s products. There is an option for two, one-year extensions on the agreements. Under these agreements, Cangene will continue to supply WinRho(R) SDF (Rho D Immune Globulin (human) for Injection) and VariZIG(TM) (Varicella Zoster Immune Globulin (Human)) and will now supply HepaGam B(TM) (Hepatitis B Immune Globulin (Human) Injection) for preventing recurrence of hepatitis B virus infection following liver transplantation.
